Perturbational similarity maps are among the most ambitious artifacts in modern biology. The idea is elegantly simple: knock out or repress thousands of genes one at a time, record the molecular or cellular consequences of each perturbation, and then compare those consequence profiles to one another. Genes whose disruptions produce similar effects are inferred to act in the same pathways or protein complexes, turning a mountain of raw screening data into a functional network. If such maps were transferable, a perturbation atlas painstakingly assembled in one system, for example the mouse brain, could be used to interpret screens performed in human cell lines, dramatically multiplying the value of expensive experiments and accelerating the translation of animal findings into human biology.

Testing that assumption required a careful matching infrastructure. Wen began by restricting the comparison to genes with strict one-to-one orthology between mouse and human, a conservative choice that retained 71 shared perturbation targets for comparison with the K562 Perturb-seq dataset, 90 for the RPE1 Perturb-seq dataset, 695 for HeLa morphology profiles from the PERISCOPE resource, and between 273 and 311 for nine L1000 cell-line matrices. Even before any statistics were computed, the attrition was striking: the vast majority of perturbations profiled in any single system simply have no directly comparable counterpart in the others, a practical constraint that any cross-system transfer strategy must confront.

The core of the analysis rested on three complementary endpoints, each designed to probe a different notion of transferability. The first was global pair-rank concordance: if two perturbed genes are ranked as similar neighbors within the mouse brain map, do they receive similar ranks in the human datasets? This was quantified with Spearman rank correlation across all pairs of shared targets. The second was source-defined top-k neighbor preservation, a stricter test asking whether a perturbation’s ten nearest neighbors in the source map remain among its top neighbors in the target dataset. The third was within-validation retrieval against CORUM, a curated database of protein complexes, which checks whether external perturbation matrices show internal structure consistent with known molecular assemblies.

The headline numbers were sobering. Under the primary zero-anchored root-mean-square representation of the response features, the Spearman correlation between mouse and human pair ranks was 0.026 in K562 and 0.035 in RPE1, effectively indistinguishable from zero. The two HeLa morphology conditions yielded correlations of 0.0022 and 0.0055, and across the nine L1000 cell lines the median was 0.0055. In other words, knowing which perturbations resemble each other in the mouse whole-brain atlas provided essentially no information about which perturbations resemble each other in any of these human systems. The neighbor-preservation test fared no better: across all thirteen tested contexts, not a single source-defined top-10 preservation result survived statistical correction for multiple comparisons, with the smallest adjusted q-value reaching only 0.240.

One of the study’s most technically important findings concerns how sensitive these conclusions are to the mathematical representation of the data. Perturbation profiles are high-dimensional vectors, and the choice of how to normalize and scale them can reshape the geometry of the entire map. When Wen switched from the primary zero-anchored RMS representation to across-target standardization in the RPE1 dataset, the correlation rose to 0.102, with a 95 percent confidence interval of 0.027 to 0.201, a weak but statistically detectable signal. Omitting the feature RMS scaling step instead produced a descriptive correlation of negative 0.034. The lesson is double-edged: representation choices can manufacture or destroy apparent transferability, which means that any published claim of cross-system concordance must report and justify its preprocessing pipeline in detail.

The study also probed the reliability of the maps themselves, asking how much of the failure to transfer could be blamed on noise within each dataset. Across fifty random cell-level splits of the K562 and RPE1 Perturb-seq data, the median global correlation between independently derived maps was 0.600 and 0.710 respectively, with top-10 neighbor overlap of roughly 0.50. Across fifty mouse-level splits of the K562- and RPE1-matched source profiles, the median global correlations were 0.731 and 0.703. These figures indicate that the individual maps are internally reproducible to a moderate degree, yet they also reveal substantial split-to-split variability. Crucially, Wen notes that a true cross-species noise ceiling, the maximum correlation one could expect even for perfectly transferable biology given measurement noise, remains unestimated, so the near-zero observed correlations cannot yet be cleanly separated from an unfavorable signal-to-noise regime.

The within-validation CORUM analysis added an important nuance. Several of the external human matrices did show evidence of protein-complex structure when analyzed on their own terms, meaning that perturbations targeting members of the same complex tended to cluster together within those datasets. But Wen is careful to point out that this result does not test preservation of the source map’s neighbor structure; a dataset can be internally biologically coherent while remaining globally discordant with the mouse brain atlas. This distinction matters for the field because within-dataset validation is often presented as evidence of quality, when the more demanding question, whether functional structure survives the journey between systems, is a separate and harder test.

The implications reach well beyond cell culture. In vivo Perturb-seq has recently been used to map transcriptional networks in the developing cortex, to dissect astrocyte function, and to link psychiatric disease risk genes to specific molecular mechanisms, and such whole-brain atlases are increasingly proposed as reference resources for interpreting human genetic data. The new results do not invalidate that enterprise, but they do impose a discipline: conclusions drawn from a perturbation map in one species or modality should not be assumed to hold in another without direct empirical verification, and the choice of feature representation must be treated as a first-class scientific decision rather than a technical afterthought.

Wen is equally explicit about the limits of the negative findings. The results are conditional on the specific representations and feature selections tested, they concern non-neural human systems that differ profoundly from brain tissue, and they do not establish that transferability is absent, particularly for neural systems where matched perturbation data do not yet exist at comparable scale. The analysis code, fixed random seeds, processed inputs, and reviewer-requested analyses have been deposited in a versioned Zenodo archive, and the underlying public datasets from the whole-brain atlas, the Replogle Perturb-seq screens, PERISCOPE, and the Connectivity Map remain freely available. That transparency should make it straightforward for other groups to extend the audit, perhaps to neural organoids, assembloid screens, or emerging spatial Perturb-seq platforms, as those resources mature. For now, the study stands as a rigorous caution: in perturbational genomics, the map is not yet the territory, and every boundary between species, cell systems, and assay modalities must be tested rather than assumed.

Subject of Research: Cross-species and cross-platform transferability of perturbational similarity maps in functional genomics

Article Title: Testing the Transferability of Perturbational Similarity Maps Across Species, Cell Systems, and Assay Modalities

Article References: Wen, J. (2026). Testing the Transferability of Perturbational Similarity Maps Across Species, Cell Systems, and Assay Modalities. Neuroinformatics, 24(4), Article 66. https://doi.org/10.1007/s12021-026-09821-1

Image Credits: AI Generated

DOI: 10.1007/s12021-026-09821-1

Keywords: Perturb-seq, Neuroinformatics, perturbation atlas, cross-species comparison, L1000, Connectivity Map, protein complexes, CORUM, reproducibility, representation transfer, CRISPR screens, whole-brain mapping

The term dark proteome covers an astonishing diversity of molecular species. It includes proteins translated from non-canonical open reading frames — stretches of RNA that were long dismissed as non-coding filler — as well as products of repeat elements such as endogenous retroviruses and LINE-1 transposons, peptides derived from circular RNAs, mistranslated proteins produced when the ribosome inserts the wrong amino acid, proteasomally spliced peptides, and stress-induced translation products that appear only when cells are pushed to the brink. Over the past decade, an unprecedented depth of resolution has been attained in cataloguing this hidden world, with individual classes of dark proteins now numbering in the thousands of members each. A massive proteogenomic screen published in 2024, for example, identified thousands of novel peptides from the human dark proteome, and a 2026 study in Nature expanded the human proteome with microproteins and peptideins — molecules with evidence for their existence but ambiguous or absent evidence for physiological function in normal cells.

The technological engine behind this discovery wave is ribosome profiling, or Ribo-seq, a technique first developed in Weissman’s laboratory that captures snapshots of every ribosome engaged on every messenger RNA in a cell. Ribo-seq revealed that translation is far more pervasive than textbook models suggested: ribosomes initiate not only at annotated start codons but at hundreds of thousands of upstream and alternative sites, in long non-coding RNAs, in 5′ untranslated regions and even in pseudogenes. Complementing Ribo-seq, immunopeptidomics — the mass spectrometric analysis of peptides presented on the cell surface by major histocompatibility complex molecules — has shown that a striking fraction of the peptides displayed by cancer cells comes from these unannotated sources. Studies in melanoma, lung cancer and pancreatic cancer have demonstrated that noncoding and non-canonical regions are among the main sources of targetable tumour-specific antigens, fundamentally challenging the assumption that neoantigens arise mainly from point mutations in canonical genes.

What makes the dark proteome more than a curiosity is the accumulating evidence that its members do real work in cancer biology. Individual dark proteins have now been characterized as oncogenes, tumour suppressors, signalling regulators and cancer-specific genetic dependencies. The microprotein TPM3P9, encoded by a cryptic long non-coding RNA, drives oncogenic RNA splicing and tumorigenesis. The TINCR ubiquitin-like microprotein acts as a tumour suppressor in squamous cell carcinoma, while a related microprotein called pTINCR promotes epithelial differentiation and suppresses tumour growth through activation of the CDC42 protein. In glioblastoma, a peptide encoded by the upstream open reading frame of the MYC messenger RNA binds to the tropomyosin receptor kinase B and promotes tumour growth in mice, and the upstream-ORF-encoded MP31 disrupts mitochondrial quality control and inhibits tumorigenesis. In childhood medulloblastoma, translation of non-canonical open reading frames appears to function as a cancer cell survival mechanism in its own right.

Perhaps the most dramatic examples come from dual-coding genes — loci where a single stretch of DNA yields both a canonical protein and a second, unconventional product. The NCYM gene, a cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β and thereby stabilizes MYCN in human neuroblastomas, a finding that has been linked to clinical outcome. The classic CDKN2A tumour suppressor locus encodes not only p16INK4A but also p14ARF, an alternative reading frame product that forms meso-scale assemblies upon phase separation with the nucleolar protein NPM1. Even the circular RNA world has yielded a functional oncogene: Firefox, a protein encoded by circular PVT1 RNA, was shown in 2026 to be essential for MYC-driven oncogenesis. These cases demonstrate that the dark proteome is not merely translational noise but a layer of biology with direct consequences for tumour evolution and treatment response.

How does cancer gain access to this hidden protein repertoire? The Perspective outlines several mechanisms of dysregulation. Oncogenic transcription factors, particularly chimeric fusion proteins characteristic of certain leukaemias and sarcomas, can drive tumour-specific transcription, processing and translation of silent genomic regions, effectively switching on genes that were never meant to be expressed. Extrachromosomal DNA — circular DNA molecules that carry amplified oncogenes such as MYC in pancreatic cancer — can generate fusion transcripts and aberrant translation products at high levels. Nutrient stress provides another route: when tumours experience tryptophan or arginine deprivation, the ribosome misincorporates substitute amino acids, generating so-called substitutants that are foreign to the immune system. Chemotherapy and leucine deprivation likewise induce codon-biased aberrant protein production. Meanwhile, oncogene-driven sloppiness in mRNA translation, ribosomal frameshifting and stress-response pathways such as the integrated stress response and the unfolded protein response all conspire to flood the cancer cell with non-canonical peptides, many of which end up displayed on the cell surface.

It is on the immunotherapy front that the dark proteome may deliver its most immediate clinical payoff. Because many dark proteins are encoded by genomic regions that are not expressed in healthy tissues, the immune system has never been trained to tolerate them, making their peptides potentially ideal tumour antigens. Endogenous retrovirus-derived antigens have already been shown to promote lung cancer immunotherapy, and antibodies against these ancient viral proteins correlate with response to checkpoint blockade. Shared epitopes from endogenous retroviruses can induce high-avidity cytotoxic T cells, and tumour circular RNAs have been shown to elicit anti-tumour immunity by encoding cryptic peptides. In pancreatic cancer, tumour-restricted cryptic antigens have been validated as targets for T cell recognition. The therapeutic modalities now in play span the full modern immunotherapy arsenal: personalized and shared vaccines, TCR-engineered T cells, CAR-T cell approaches and bispecific T cell engagers. A first-in-class bispecific T cell engager targeting a DARKFOX peptide presented by solid tumours has already entered preclinical development, and a clinical trial of a dark-proteome-directed immunotherapy is registered on ClinicalTrials.gov.

Turning dark proteins themselves into drug targets is harder, but not impossible. Many are small, intrinsically disordered molecules that lack the stable pockets conventional small-molecule drugs require. Yet structure prediction tools such as AlphaFold, together with new protein design methods for binding intrinsically disordered regions, are beginning to make the undruggable tractable. The MYC inhibitor omomyc — a miniprotein that exploits intrinsic cell-penetrating activity — has advanced to a phase 1 clinical trial in solid tumours, and a synthetic cell-penetrant miniprotein called DuoMYC efficiently inhibits oncogenic MYC. EMBOW-derived peptides targeting the WDR5-MLL1 complex have suppressed leukaemia progression in preclinical models. Functional genomics is doing the other half of the work: CRISPR-based screens have revealed that human cancer cells depend on cryptic non-canonical open reading frames, and large-scale short open reading frame screens have identified microproteins involved in cancer cell fitness, feeding into resources such as the cancer dependency map and the dark kinase knowledgebase.

The authors are careful to emphasize how much remains unknown. Key gaps persist in understanding how the dark proteome is regulated, how much it actually contributes to cancer phenotypes versus representing tolerated noise, how antigenic its products truly are in patients, and whether dark proteins can be developed into clinical-grade therapies with acceptable safety profiles. Community efforts to standardize the annotation of translated open reading frames, benchmark mass spectrometric detection of unannotated microproteins and expand reference catalogues such as GENCODE are underway, supported by initiatives including the Cancer Grand Challenges dark proteome teams. Spatial transcriptomics and single-cell Ribo-seq are adding tissue-level context, revealing where and when unconventional translation occurs in intact tumours. What is clear is that the dark proteome offers the possibility to advance cancer science, diagnosis and treatment in ways the genomics revolution alone could not. The darkness, the authors suggest, is not a void but an unexplored continent — and the maps are finally being drawn.

Subject of Research: The functional dark proteome in cancer, comprising non-canonical proteins and peptides with roles in tumour biology and immunotherapy

Article Title: Mapping the functional dark proteome in cancer

Article References: Prensner, J. R., Freed-Pastor, W. A., Abelin, J. G., Wu, C. J., Merbl, Y., Pilpel, Y., Schumacher, T. N., Weissman, J. S., van Heesch, S., & Agami, R. (2026). Mapping the functional dark proteome in cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00985-1

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00985-1

Keywords: dark proteome, cancer, non-canonical open reading frames, microproteins, Ribo-seq, immunopeptidomics, neoantigens, cancer immunotherapy, CRISPR screens, tumour suppressors, oncogenes, translational dysregulation

The story begins with glioblastoma, the most aggressive form of adult brain cancer. Despite surgery, radiation and chemotherapy, median survival remains roughly 14.6 months, and a major reason is the persistence of glioblastoma stem cells, which drive tumor initiation, progression and resistance to therapy. Because aberrant epigenetic programs help these cells maintain their plasticity, the researchers had previously screened a library of epigenetic chemical probes and found that QC6352 suppressed glioblastoma stem cell viability at nanomolar concentrations. In the new study, the team validated that potency across six patient-derived glioblastoma stem cell lines, including RKI1, MMK1, JK2, FPW1, HW1 and GBM6, with growth-inhibition potency values ranging from 3 to 133 nanomolar. Live-cell imaging showed that nearly 80 percent of treated cells arrested in the G0/G1 phase of the cell cycle, and the drug left normal human astrocytes unharmed up to 1 micromolar, a tenfold therapeutic window.

The cellular phenotype was striking. Treated cells ramped up expression of senescence and apoptosis genes, accumulated senescence-associated beta-galactosidase and Annexin V staining, and lost expression of stemness markers such as NES, SOX2 and SOX9, shifting toward a nonproliferative, differentiated state. In mice bearing orthotopic GBM6 xenografts, QC6352 at 100 milligrams per kilogram slowed tumor growth and extended median survival from 28.5 to 34.5 days without affecting body weight or blood counts. On the surface, everything pointed to a spectacular epigenetic vulnerability. But the team, led by Lenka Munoz of the University of Sydney together with Paul Workman, applied a discipline that is recommended far more often than it is practiced: testing multiple, structurally distinct inhibitors against the presumed target.

That discipline exposed the crack. Alongside QC6352, the researchers evaluated the orthogonal KDM4 inhibitor ML324, which they confirmed inhibits KDM4A with essentially the same biochemical potency, an IC50 of 326 nanomolar versus 355 nanomolar for QC6352. Yet the two compounds behaved nothing alike in cells. While QC6352 at 100 nanomolar completely repressed glioblastoma growth and triggered apoptosis, ML324 at 500 nanomolar had no impact whatsoever, and even at 5 micromolar it failed to block colony formation. Both compounds raised the levels of the histone marks H3K9me3 and H3K36me3 that KDM4 enzymes normally remove, but the team cautioned that such changes can also reflect broader heterochromatin and senescence responses, so they went further, directly testing whether either drug actually engaged KDM4 proteins inside living cells.

It did not. Cellular thermal shift assays detected no stabilization of overexpressed KDM4A even at 100 micromolar of either compound, and single-molecule tracking of SNAP-tagged KDM4A in live HeLa cells revealed no change in the mobility or chromatin-binding behavior of the enzyme after drug treatment. Expression analysis deepened the skepticism: KDM4A and KDM4B transcripts were present at low levels in only some glioblastoma stem cell lines, KDM4C and KDM4D were largely undetectable across twelve lines, and single-cell RNA sequencing of biopsies from 62 patients showed consistently low KDM4 expression in malignant cells. Proteomics found no KDM4 protein at all in A172 glioblastoma cells. Crucially, knocking out KDM4A, KDM4B or KDM4C individually with CRISPR-Cas9 left cells just as sensitive to QC6352 as before, and genome-wide CRISPR dropout screens using the 71,090-guide TKOv3 library identified 3,334 fitness genes in RKI1 cells without a single KDM4 family member among them.

The chemogenomic screens added another layer. Treating TKOv3-transduced cells with QC6352 at its 90 percent effective concentration of 70 nanomolar and at its 20 percent effective concentration of 25 nanomolar revealed 609 sensitizing and 278 resistance genes, with RNA splicing and mRNA and tRNA processing emerging as key biological processes. Again, no KDM4 enzyme met the threshold. The evidence was converging on an uncomfortable conclusion: the celebrated KDM4 probe was doing something else entirely in glioblastoma cells.

To find the real mechanism, the team turned QC6352’s transcriptional fingerprint into a search query against the Connectivity Map, comparing its signature with more than 20,000 pharmacologic perturbations across 71 cell lines. The top matches were brequinar, a known DHODH inhibitor, and floxuridine and raltitrexed, both inhibitors of thymidylate synthase. All three converge on a single metabolic pathway: de novo pyrimidine synthesis, the assembly line that produces the nucleotide building blocks of DNA, RNA and lipids. The logic of the pathway also explained a curious secondary hit, the cardiac glycosides digoxin, strophanthidin and bufalin, which indirectly block the uridine salvage route by suppressing sodium-dependent nucleoside uptake. When the researchers simply added uridine to the culture medium, it completely rescued glioblastoma cells from QC6352-induced growth arrest, the classic signature of a blocked pyrimidine supply.

Biochemistry then delivered the decisive numbers. In a recombinant enzyme assay, QC6352 inhibited human DHODH with an IC50 of 0.3 nanomolar, making it more potent than the established DHODH inhibitors BAY2402234 at 1.1 nanomolar and brequinar at 2.6 nanomolar. ML324, by contrast, showed no DHODH inhibition at all. Metabolomics sealed the case: within 24 hours of treatment, both QC6352 and BAY2402234 drove a roughly 10,000-fold accumulation of the upstream DHODH substrates dihydroorotate and carbamoylaspartate while depleting the downstream nucleotides UMP, UDP and UTP. A 1.95-angstrom cocrystal structure of QC6352 bound to human DHODH showed the compound occupying the hydrophobic channel leading to the active site, blocking ubiquinone cofactor binding, with its isonicotinic acid head forming polar contacts with R136, Q47 and Y356 and its tail packing into a hydrophobic tunnel. The same scaffold, in the KDM4A structure, chelates the catalytic nickel ion, explaining how one molecule can moonlight in two entirely different enzyme families.

The clinical implications came into sharp focus with zavondemstat, a structural analog of QC6352 now in trials for advanced and metastatic cancers. The R-enantiomer inhibited DHODH at 0.6 nanomolar, outperforming brequinar, farudodstat and BAY2402234, while its S-enantiomer was 40-fold weaker against DHODH, a chirality-dependent potency gap that tracked far better with the compounds’ cellular efficacy than their modest twofold difference in KDM4A inhibition. Uridine fully reversed the effects of both enantiomers, and expressing an inhibitor-resistant DHODH A58T mutant rescued cells from QC6352, zavondemstat and BAY2402234 alike, while uridine could not rescue the unrelated drugs GSK-J4 or doxorubicin. Guided by the crystal structures, the team even designed three new isonicotinic acid analogs that retain potent KDM4A inhibition, with IC50 values between 41 and 208 nanomolar, while showing no DHODH activity above 20 micromolar, providing the field with genuine KDM4-selective probes for the first time in this chemical series.

Beyond glioblastoma, the study is a cautionary tale for chemical biology as a whole. Despite long-standing guidelines urging the use of at least two structurally distinct probes plus inactive controls, reliance on a single compound remains common, and QC6352 shows exactly how that shortcut can produce confident but wrong conclusions about drug mechanism. DHODH itself is a validated therapeutic target, with the inhibitors leflunomide and teriflunomide already approved for autoimmune disease, though no DHODH inhibitor has yet been approved for cancer. The authors note that zavondemstat’s KDM4-independent mechanism does not diminish its clinical promise, and may even explain it, but they urge that ongoing trials be benchmarked against prior DHODH inhibitor studies. They also flag that DHODH should now be considered a frequent hidden target in phenotypic drug discovery, since multiple unrelated chemotypes keep landing on it. For glioblastoma, a disease desperate for options, the message is paradoxically hopeful: a drug already in the clinic may work through a metabolic vulnerability that is increasingly recognized as one of cancer’s most druggable Achilles heels.

Subject of Research: Target deconvolution of the KDM4 inhibitor QC6352 revealing DHODH as the driver of antiglioblastoma activity

Article Title: DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells

Article References: Sterling, J. R., Holtsmark, J. R., Joun, G. L., Graus, M. S., Du, T. Y., Kuchibhotla, M., Johns, T. G., deWeck, A., Loo, L., Neely, G. G., Tran, K., Shard, C., Gomez, G. A., Patil, A., Shi, D. D., Losman, J.-A., Saxton, A. J., Baker, J. R., Lei, Z., … Munoz, L. (2026). DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02306-x

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02306-x

Keywords: glioblastoma, DHODH, QC6352, zavondemstat, KDM4, pyrimidine biosynthesis, chemical probes, target deconvolution, epigenetics, drug mechanism, cancer metabolism, CRISPR screens

DNMT3A is one of the principal enzymes responsible for establishing DNA methylation patterns, the chemical marks that help determine which genes are switched on or off. Mutations in the gene encoding DNMT3A are among the most frequent alterations in acute myeloid leukemia and other hematologic malignancies, and they have also been observed in solid tumors. Yet the clinical behavior of DNMT3A-mutant cancers has often appeared contradictory. In some settings, loss of DNMT3A seems to sensitize tumors to immune attack; in others, it appears to help malignant cells escape immune surveillance. The new screening effort was designed to resolve this paradox by asking, at whole-genome scale, what happens when DNMT3A and its interaction partners are perturbed inside tumors that are actively fighting off an immune response.

The researchers used CRISPR-based genetic screens conducted in vivo, a technique that allows scientists to disable thousands of genes simultaneously in tumor cells and then observe which perturbations change the tumors’ fate inside a living animal with an intact immune system. This approach is far more faithful to real tumor biology than conventional in vitro screens because it captures the full complexity of the tumor microenvironment, including cytotoxic T cells, natural killer cells, macrophages, and the inflammatory signals that coordinate an immune response. Tumor cells carrying a library of gene-targeting guide RNAs were implanted into immunocompetent hosts, and the guide RNAs that became enriched or depleted over time revealed which genes the tumors depended on to survive immune pressure.

The results pointed repeatedly to DNMT3A and the molecular machinery surrounding it. When the screens interrogated tumors under strong immune selection, loss of DNMT3A function emerged as a route through which tumor cells could reshape their epigenetic landscape in ways that dampen immune recognition. The data indicate that DNMT3A normally helps maintain the expression of molecules that the immune system uses to identify and eliminate cancerous cells. When that maintenance is lost, the resulting methylation changes can silence antigen presentation components and interferon-responsive genes, effectively lowering the tumor’s visibility to patrolling cytotoxic lymphocytes. In this role, DNMT3A functions as a guardian of immunogenicity, and its absence gives tumors a survival advantage in the face of immune attack.

At the same time, the screens revealed a second, opposing role. In other contexts, intact DNMT3A activity appeared to support immune evasion through a different mechanism: the enzyme’s methyltransferase function can reinforce transcriptional programs that suppress inflammatory signaling within the tumor. By methylating and repressing specific regulatory regions, DNMT3A can help keep certain immune-stimulatory genes quiet, allowing tumor cells to persist even when inflammatory cytokines such as interferon gamma are present in the microenvironment. The dual functions mean that the consequence of altering DNMT3A is not straightforward. Whether restoring or inhibiting the enzyme benefits the patient depends on which of its activities dominates in a given tumor and which immune pressures that tumor faces.

This duality has immediate implications for the growing number of clinical strategies that target DNA methylation. Hypomethylating agents such as azacitidine and decitabine are already used to treat myelodysplastic syndromes and certain leukemias, and there has been intense interest in combining these drugs with immune checkpoint inhibitors, on the theory that demethylation can unmask tumor antigens and make tumors more visible to T cells. The new findings refine that logic. If DNMT3A loss itself can drive immune evasion by silencing antigen presentation, then simply erasing methylation marks may not uniformly increase immunogenicity. Instead, the specific genes reactivated or repressed by demethylating treatment, and the baseline status of DNMT3A in the tumor, could determine whether combination immunotherapy helps or hurts.

The screening platform also identified genes that cooperate with DNMT3A in these immune-related functions, mapping a network of epigenetic regulators, interferon pathway components, and antigen presentation machinery that together control the tumor-immune interface. Perturbing members of this network produced effects that converged on the same phenotypes seen with DNMT3A disruption, strengthening the conclusion that DNA methylation homeostasis is a central determinant of immune recognition. Notably, the in vivo setting was essential for detecting many of these effects. Parallel analyses in culture conditions did not fully reproduce the immune-dependent phenotypes, underscoring how microenvironmental pressure sculpts which genetic dependencies actually matter in cancer.

For patients with DNMT3A-mutant malignancies, the work offers a framework for thinking about why responses to immunotherapy vary so widely. Clonal hematopoiesis, the age-related expansion of blood cells carrying DNMT3A mutations, affects a large fraction of older adults and is increasingly recognized as a factor that modifies cancer risk and treatment outcomes. The new results suggest that the same epigenetic rewiring that characterizes DNMT3A-mutant clones may influence their visibility to the immune system, with potential consequences for both cancer development and the efficacy of immune-based therapies. Measuring the immune-evasion programs identified in the screens could help stratify patients and predict who is most likely to benefit from checkpoint blockade or epigenetic drug combinations.

Technically, the study demonstrates the power of pooled CRISPR screening performed inside living hosts as a discovery engine for cancer immunology. Rather than cataloging gene expression differences after the fact, in vivo screens impose real selective pressure and let the organism reveal which genes determine survival. The enrichment and depletion patterns of guide RNAs, analyzed by sequencing, provide a genome-wide functional map of immune evasion that would be nearly impossible to assemble through observation alone. The strategy also highlights the value of testing epigenetic regulators under immune pressure, since their roles are inherently context-dependent and often invisible in simplified experimental systems.

The researchers emphasize that the dual functions of DNMT3A open multiple therapeutic avenues. In tumors where DNMT3A loss silences immune recognition, interventions that restore antigen presentation or reconstitute interferon signaling could resensitize cancer cells to immunotherapy. In tumors where DNMT3A activity actively suppresses inflammatory genes, inhibiting the enzyme’s methyltransferase function might unleash the immune-stimulatory programs the tumor has been holding in check. Distinguishing between these states will require biomarkers that report on the enzyme’s downstream methylation targets, an effort the screening data now make more concrete. As epigenetic therapies continue to merge with cancer immunotherapy, the lesson from this study is that the epigenetic state of a tumor is not merely background biology; it is an active, manipulable determinant of whether the immune system can see and destroy the cancer, and DNMT3A sits at the fulcrum of that decision.

Subject of Research: In vivo CRISPR screening of DNMT3A's dual roles in tumor immune evasion

Article Title: In vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion

Article References: In vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion. (n.d.). https://doi.org/10.1038/s41467-026-77495-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77495-z

Keywords: DNMT3A, CRISPR screens, tumor immune evasion, DNA methylation, immunotherapy, epigenetics, Nature Communications, antigen presentation, interferon signaling, cancer genetics, in vivo screening, tumor microenvironment

The new study, published in the Journal of Experimental & Clinical Cancer Research, centers on BRN2, a transcription factor encoded by the POU3F2 gene. Transcription factors are proteins that bind to DNA and switch other genes on or off, and BRN2 has long been associated with aggressive, invasive melanoma behavior. Previous work had hinted at a connection between BRN2 and anoikis resistance, but the precise signaling cascade through which BRN2 keeps suspended cells alive remained unknown. The research team, led by Hannah M. Neuendorf, Jacinta L. Simmons and Glen M. Boyle, spanning QIMR Berghofer Medical Research Institute, Queensland University of Technology and the University of Queensland, set out to close that gap using an unusually powerful combination of genetic screening, chemical probes and proteomic analysis.

To confirm that BRN2 genuinely drives anoikis resistance rather than merely correlating with it, the investigators deployed genome-wide CRISPR screens. These screens use the CRISPR gene-editing machinery in two complementary modes: CRISPR activation, which ramps up gene expression, and CRISPR inhibition, which dials it down using a nuclease-dead form of the Cas9 protein fused to repressive domains. By applying these screens to human melanoma cell lines grown in ultra-low attachment plates, conditions that force cells to survive without their usual anchoring to the extracellular matrix, the researchers could see which genes helped or hindered survival in suspension. The results validated BRN2 as a bona fide driver of anoikis resistance. When BRN2 was suppressed, melanoma cells that had previously shrugged off detachment became markedly more sensitive to death by anoikis.

Genetic validation alone, however, does not yield a drug. The team therefore turned to small molecule inhibitors designed to bind the BRN2 protein directly. These chemical probes, referred to in the study as B18 and B18-94, were synthesized and characterized in detail, including nuclear magnetic resonance spectra and crystallographic analysis of their structures. In melanoma cell lines with acquired anoikis resistance, treatment with the inhibitors restored sensitivity to anoikis under ultra-low attachment conditions. The effect was measured by flow cytometry, with cells stained with propidium iodide and calcein dyes to distinguish living from dying populations over seven days in suspension culture. Across multiple resistant cell lines, including MM383, C-32 and MM386, the compounds substantially reduced the fraction of cells that survived detachment.

To understand what BRN2 inhibition actually does inside the cell, the researchers used the small molecules as probes for quantitative mass spectrometry, a technique that measures the abundance of thousands of proteins simultaneously. The proteomic fingerprints that emerged pointed squarely at the mitochondria, the membrane-bound organelles that generate most of a cell’s chemical energy. BRN2 inhibition increased oxidative phosphorylation, the mitochondrial energy-production process, and raised the expression of a protein called AIFM2. The consequence was apoptosis, the standard cellular suicide program, accompanied by mitochondrial fragmentation, a physical collapse of the organelle’s normal tubular network into disconnected pieces. In other words, BRN2 appears to keep suspended melanoma cells alive by promoting a state of mitochondrial dysfunction that somehow shields them from apoptotic signals, and removing BRN2 dismantles that protection.

The study also traced the upstream wiring. According to the authors, BRN2 drives anoikis resistance through the MAPK and NF-κB signaling pathways, which leads to dysregulation of PPARγ, a nuclear receptor involved in metabolism and cell fate. This signaling chain ultimately produces the mitochondrial changes observed in the proteomics data. The team also examined STAT3, another signaling protein implicated in melanoma survival, and measured changes in its phosphorylation state following inhibitor treatment. Together, these findings sketch a coherent circuit: an anchorage-independent cell relies on BRN2-dependent transcriptional programs to keep its mitochondria in a configuration that permits survival, and disrupting BRN2 collapses that program from the top down.

Perhaps the most clinically significant result involves vemurafenib, a BRAF inhibitor that transformed treatment for melanoma patients carrying BRAF mutations but whose benefits are often eroded by resistance. When the researchers combined BRN2 inhibitors with vemurafenib, the melanoma cells became significantly more sensitive to killing by the BRAF-targeted drug. Synergy assays, analyzed using the Highest Single Agent model, demonstrated that the combination was more effective than either treatment alone, both in standard adherent culture and in ultra-low attachment conditions that mimic the suspension phase of metastasis. For the first time in melanoma models, the study shows that pharmacological inhibition of BRN2 can sensitize cells to BRAF-targeted therapy, suggesting a potential strategy for extending the reach of existing medicines.

The implications extend beyond drug combination. Because anoikis resistance is thought to be essential for cancer cells to survive the journey from a primary tumor to a distant site, a therapy that reverses this resistance could theoretically prevent the seeding of metastatic disease before it begins. The researchers note that inhibiting BRN2 may block metastasis at one of its most vulnerable steps, the period when circulating tumor cells are unanchored and exposed. That idea remains to be tested in clinical settings, and the compounds used in this study are research probes rather than approved medicines. Nonetheless, the demonstration that a transcription factor once considered undruggable can be chemically inhibited with functional consequences opens a path that many in the field had regarded as difficult.

The work also carries broader lessons for cancer biology. Anoikis resistance is not unique to melanoma; it is a hallmark of many carcinomas and contributes to tumor formation and progression across cancer types. By identifying mitochondrial dysfunction as the mechanistic bridge between BRN2 activity and survival in suspension, the study adds to a growing body of evidence that metabolic state and cell death sensitivity are deeply intertwined. It also showcases a methodological template: genome-wide CRISPR screens to find the driver, selective small molecules to interrogate and disable it, and quantitative proteomics to map the downstream consequences. The research was supported by an Australian Government Research Training Program Scholarship and a philanthropic donation from Brian and Merle Dwyer, and the authors report no competing interests. As the scientific community awaits follow-up studies in animal models and, eventually, clinical candidates, the message of this work is clear: the molecular machinery that lets melanoma cells travel unafraid through the body can be targeted, and doing so may render one of medicine’s most stubborn cancers considerably more defenseless.

Subject of Research: BRN2-driven anoikis resistance in melanoma and its reversal by small molecule inhibitors

Article Title: Inhibition of BRN2 in melanoma reverses anoikis resistance and sensitizes cells to killing by vemurafenib

Article References: Neuendorf, H. M., He, X., Adams, M. N., Chow, S., Tran, K. A., Smith, A. G., Bernhardt, P. V., Williams, C. M., Simmons, J. L., & Boyle, G. M. (2026). Inhibition of BRN2 in melanoma reverses anoikis resistance and sensitizes cells to killing by vemurafenib. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03819-y

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03819-y

Keywords: melanoma, BRN2, anoikis resistance, vemurafenib, CRISPR screens, mitochondria, metastasis, targeted therapy, AIFM2, BRAF inhibitor, transcription factor, proteomics